Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
low-dose influenza vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The low-dose influenza vaccine (GSK1247446A) is an investigational trivalent inactivated split-virion vaccine developed by GSK Biologicals for the prevention of seasonal influenza in adults aged 60 years and older. It contains a reduced dose of hemagglutinin (HA) antigens from three influenza strains, formulated with GSK's proprietary AS03 adjuvant system—an oil-in-water emulsion containing squalene, alpha-tocopherol, and polysorbate-80. By utilizing the adjuvant to compensate for the lower antigen content, the vaccine aims to elicit protective haemagglutination-inhibition (HI) antibody titers comparable to or better than standard-dose vaccines while potentially improving the efficiency of vaccine production. It has been evaluated in Phase II clinical trials to assess its immunogenicity and safety profile.
- Other names
- low-dose AS03-adjuvanted influenza vaccineAS03-adjuvanted low-dose trivalent inactivated influenza vaccineAS-03-adjuvanted low-dose trivalent inactivated influenza vaccineAS 03-adjuvanted low-dose trivalent inactivated influenza vaccine
02
Targets
HA (Hemagglutinin)M1 (Muscarinic acetylcholine receptor M1)NP (Influenza virus nucleoprotein)Neuraminidase
Beyond the preview
Go deeper on low-dose influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on low-dose influenza vaccine.